Leap Therapeutics Company Insiders

Leap Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.5805) % which means that it has lost $0.5805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0718) %, meaning that it created substantial loss on money invested by shareholders. Leap Therapeutics' management efficiency ratios could be used to measure how well Leap Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.35 in 2025. Return On Capital Employed is likely to rise to -1.24 in 2025. At this time, Leap Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2025, whereas Total Assets are likely to drop slightly above 45.2 M in 2025. Common Stock Shares Outstanding is likely to rise to about 24.7 M in 2025, despite the fact that Net Loss is likely to grow to (46.7 M).

Leap Therapeutics Workforce Comparison

Leap Therapeutics Insider Trading

Leap Therapeutics Notable Stakeholders

The success or failure of an entity such as Leap Therapeutics often depends on how effective the management is. Leap Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Leap management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Leap management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Leap Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Leap Therapeutics. Check Leap Therapeutics' Beneish M Score to see the likelihood of Leap Therapeutics' management manipulating its earnings.

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.